Full-Time
QA Associate
Posted on 9/25/2025
Twist Bioscience
1,001-5,000 employees
Produces synthetic DNA for research.
Compensation Overview
$24 - $31/hr
San Bruno, CA, USA
Hybrid
 QA & Testing (5) |
|---|
| , , , , |
- BS in Biology Molecular Biology, Biochemistry, Chemistry, Bioengineering or a closely- related field or equivalent work experience
- Between 2-4 years of relevant industrial experience in quality assurance
- Knowledge of quality standards (ISO 9001, ISO 13485)
- Preferably familiar with: Google Suite – mail, docs, drive, sheets, Atlassian- Confluence, JIRA. Microsoft- word, excel
- Experience in preparing for or participating in compliance audits and/or inspections by regulatory agencies.
- Excellent written and verbal communication skills
- Ability and desire for problem solving and decision making in a cross-functional team setting
- High attention to detail, excellent organizational skills, and ability to work on multiple projects with tight deadlines
- Excels in a fast-paced, team-oriented, and collaborative environment
- Proven ability to establish collaborative working relationships; team-oriented, but able to work independently
- Assist with writing work instructions and procedures, document control materials management, chage management, corrective action and preventative action (CAPA) management
- Ensure training records are up to date
- Identify and implement process improvements, as necessary
- Ensure manufacturing equipment maintenance is performed and recorded
- Ensure that standard operating procedures are followed and are appropriate for process operations
- Perform risk analysis
- Perform effectiveness checks of completed corrective and preventive actions, as needed
- Ensure compliance with company quality systems, and other company policies
- Prepare for and participates in compliance audits
- Follow regulatory and ISO 13485 requirements
- Nothing provided
Twist Bioscience designs and manufactures synthetic DNA for biotech, pharmaceutical, and research use. It uses a proprietary platform that rapidly produces custom DNA sequences and a smart algorithm to verify synthesis feasibility before production, with customers submitting requests and receiving DNA, DNA data storage, or NGS services. It differentiates itself by offering high-quality DNA at competitive prices, the ability to handle complex sequences, and an integrated platform with a broad product range for fast delivery. Its goal is to be a reliable, leading supplier of synthetic DNA and genomics tools that accelerates biotech and drug development for a wide range of clients.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South San Francisco, California
Founded
2013
Simplify's Take
What believers are saying
- 13 consecutive quarters of sequential revenue growth reaching $110.7M with 51.6% gross margins.
- Amazon Web Services partnership positions Twist as wet lab for Amazon Bio Discovery application.
- APAC revenue grew 30% and EMEA grew 22% in Q2 2026, expanding geographic footprint.
What critics are saying
- Ginkgo Bioworks scales oligo production 10x by Q3 2026, undercutting Twist's NGS pricing.
- BGI Genomics floods APAC with state-subsidized Complex Genes equivalents at half Twist's price.
- Persistent $76.58M net losses force dilutive equity raises, pressuring shareholder value through 2026.
What makes Twist Bioscience unique
- Silicon-based DNA synthesis platform synthesizes thousands of genes daily with 99.5% acceptance rate.
- AI-enabled drug discovery platform drives 28% DNA Synthesis growth and 55% Therapeutics segment expansion.
- Licensed B-Body bispecific antibody platform enables low-viscosity subcutaneous delivery for bispecific therapeutics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↓ -2%Twist Bioscience Corp stock: pioneering DNA synthesis for biotech innovation and investor opportunities. 02.04.2026 - 03:21:18 | ad-hoc-news.de Twist Bioscience Corp (ISIN: US90130A1016) leads in synthetic DNA manufacturing, enabling breakthroughs in therapeutics, agriculture, and data storage. North American investors eye its scalable platform amid growing demand for custom DNA tools. Explore business model, market position, and key watchpoints. Twist Bioscience Corp stands at the forefront of synthetic biology, offering high-throughput DNA synthesis that powers drug discovery, next-generation sequencing, and industrial biotech applications. Listed on Nasdaq under ticker TWST, its shares trade in USD, with ISIN US90130A1016 representing common stock. Investors focus on its proprietary platform's ability to disrupt traditional phosphoramidite-based synthesis methods. As of: 02.04.2026 By Elena Harper, Senior Biotech Analyst at NorthStar Market Insights: Twist Bioscience Corp exemplifies how silicon chip manufacturing principles revolutionize biological tool production in the synthetic biology sector. Core business model and technology platform. Official source All current information on Twist Bioscience Corp directly from the company's official website. Twist Bioscience Corp develops and manufactures synthetic DNA using a semiconductor-inspired process. The company prints DNA on silicon chips, achieving densities up to 10,000 times higher than conventional methods. This platform supports gene synthesis, next-generation sequencing (NGS) library prep, and antibody optimization. Key products include Twist Gene Fragments for research, Twist Expression Vectors for protein production, and Twist NGS Target Enrichment for clinical diagnostics. The scalable manufacturing reduces costs and turnaround times, addressing bottlenecks in biotech workflows. Revenue streams diversify across biopharma, academic labs, and agrotech firms. Founded in 2013, Twist went public in 2018. Its South San Francisco headquarters anchors operations, with expansion into global markets. The model emphasizes high-volume, low-cost production to capture share in a market projected to grow significantly. Market position and competitive landscape. Sentiment and reactions Twist competes with IDT (Integrated DNA Technologies), GenScript, and Eurofins Genomics in DNA synthesis. Its chip-based approach provides superior throughput and error rates below 1 in 100,000 bases. Partnerships with Illumina and Tempus bolster NGS market penetration. In biopharma, Twist's antibody libraries screen millions of variants rapidly. Agriculture clients use its tools for crop gene editing. Data storage applications explore DNA as an archival medium, with prototypes demonstrating petabyte-scale potential. Market share grows as demand for synthetic biology tools surges. North American biotech hubs like Boston and San Francisco drive adoption. Twist's IP portfolio, including process patents, fortifies barriers to entry. Sector drivers and growth catalysts. Synthetic biology benefits from advances in CRISPR, mRNA therapeutics, and personalized medicine. Regulatory approvals for gene therapies accelerate demand for custom DNA. Global health initiatives post-pandemic emphasize rapid response platforms. Twist's platform aligns with these trends, enabling faster iteration in drug development pipelines. Expansion into NGS consumables taps a recurring revenue model. Industrial biotech for sustainable materials represents a long-term opportunity. North American investors note sector tailwinds from NIH funding and VC inflows into biotech. Supply chain resilience favors U.S.-based manufacturers like Twist. Capacity expansions signal confidence in sustained demand. Relevance for north American investors. For U.S. and Canadian investors, Twist Bioscience Corp offers exposure to synthetic biology without picking individual winners in volatile end-markets. Its Nasdaq listing ensures liquidity and transparency via SEC filings. Dividend-free, growth-oriented profile suits long-term portfolios. Proximity to biotech clusters facilitates collaborations. Tax advantages for U.S. holders apply to capital gains. ESG factors highlight sustainable manufacturing versus chemical-intensive rivals. Portfolio diversification benefits from biotech weighting. Twist complements holdings in sequencing (e.g., Illumina) or CRISPR (e.g., Editas). Watch quarterly revenue breakdowns for biopharma versus NGS balance. Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. Risks and open questions. Competition intensifies as rivals scale. Technology risks include yield variability at high volumes. Dependence on biopharma cycles exposes revenue to R&D budget fluctuations. Regulatory hurdles in gene editing applications loom. Supply chain issues for reagents persist. Intellectual property challenges could arise from broad biotech patents. Open questions center on profitability timelines and market share gains. Investors monitor gross margins and cash burn rates. Geopolitical tensions may impact global expansion. What to watch next. Key catalysts include new partnership announcements and capacity utilization updates. Quarterly earnings will reveal end-market traction. Product launches in data storage merit attention. North American investors should track Nasdaq performance, sector ETFs, and peer comparisons. SEC filings provide deepest insights. Balanced exposure mitigates single-stock risks. Disclaimer: Not investment advice. Stocks are volatile financial instruments. NIS2-Richtlinie 2026: Was Geschäftsführer jetzt über Cyber-Sicherheit wissen müssen. Gratis-Leitfaden: Die neuen EU-Vorgaben zur IT-Sicherheit betreffen mehr Unternehmen als erwartet - bei Verstößen drohen persönliche Haftung und empfindliche Bußgelder. Das kostenlose E-Book "Cyber Security Awareness Trends" erklärt, welche Maßnahmen Pflicht sind und wie Sie Ihr Unternehmen mit minimalem Aufwand compliant machen. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. US90130A1016 | TWIST BIOSCIENCE CORP | boerse | 69052150 | bgmi
Petzold named JBEI Chief Information Officer. The Joint BioEnergy Institute (JBEI) announced that Chris Petzold has been appointed as Chief Information Officer (CIO), following Nathan Hillson's departure. As CIO, Petzold will be responsible for leading JBEI initiatives involving automation, data management for artificial intelligence/machine learning efforts, and data analytics. His role will also focus on driving innovation and adoption of emerging technologies related to data collection, management and analysis. Hillson has taken on a new role at Twist Biosciences. He served as JBEI's Director of Synthetic Biology Informatics since 2009, and as the CIO since July 2025. Petzold is the Deputy Vice President of Technology and Director of Functional Genomics at JBEI. His research focuses on developing mass spectrometric solutions to problems facing biofuel and bioproduct manufacturing. Recent work in the Functional Genomics group has focused on applying quantitative proteomics to metabolic engineering efforts. This work furthers the rational design and optimization of novel metabolic pathways for a wide variety of applications. Petzold obtained his PhD in Chemistry from Purdue University with an emphasis in gas-phase ion chemistry and mass spectrometric methods development. He performed his post-doctoral work at UC Berkeley, focusing on the application of mass spectrometry to glycomics and lipidomics research. He joined Jay Keasling's research group in 2005 as part of the team tasked to understand the impact of metabolic engineering on the host microbe via systems biology. In addition to his roles at JBEI, Petzold will also serve as the Interim Biodesign Department Head in the Biological Systems and Engineering (BSE) Division, leading the development of basic science discovery and technologies to enable the biomanufacturing of fuels, chemicals, and materials.
Twist Bioscience has entered into a licensing agreement with Invenra to become co-exclusive provider of Invenra's B-Body bispecific antibody platform, expanding its antibody discovery services. The platform enables development of bispecific antibodies with favourable developability characteristics and low viscosity for subcutaneous delivery. Twist will pay Invenra $5 million in cash and $15 million in stock upfront, plus acquire approximately 6% ownership in Invenra for $13.8 million in stock. Twist will receive all revenue from bispecific antibody discovery services and license revenue, whilst paying Invenra a 20% royalty on license revenue. The B-Body platform complements Twist's existing antibody discovery services, including in vivo, in vitro and AI-enabled discovery methods. The agreement allows customers to use their pre-existing monospecific antibodies within the platform.
Twist Bioscience has launched two next-generation library preparation kits powered by proprietary enzymes for clinical research applications. The Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit are designed to handle low input and challenging sample types. The TrueAmp kit utilises Twist's in-house developed polymerase and ligase to maximise coverage across difficult genomic regions whilst maintaining high accuracy. It has been validated with Twist's HT-UDI adapter system, supporting up to 3,072 unique indexes. The PCR-Free WGS kit leverages Twist's engineered ligase to convert DNA without amplification bias. It supports barcoding for up to 1,536 samples, enabling researchers to scale workflows efficiently. Both kits aim to deliver higher yields from degraded samples and reduce run failures, according to CEO Emily Leproust.
Twist Bioscience has raised its full-year revenue guidance, citing strong demand for its AI-enabled DNA and protein platforms. The synthetic biology company announced the update alongside news of expanding collaborations across discovery and research sectors. Trading at $48.12, Twist shares have risen 14.5% over the past week and 40.1% over the past month, though the company remains unprofitable with a recent net loss of $76.58 million. The company announced significant equity awards tied to recent hires to support growth initiatives. Analysts have set a price target of $49.89, approximately 3.5% above current levels. Management expects full-year revenue between $589.6 million and $621.6 million. However, Twist is not forecast to reach consistent profitability over the next three years, maintaining execution and dilution risks for investors.